The Lancet HIV in conversation with

Lise Jamieson and Gesine Mayer-Rath on cabotegravir for PrEP in South Africa

The Lancet HIV

Deputy Editor Philippa Harris talks to Lise Jamieson (Health Economics and Epidemiology Research Office, University of Witswatersrand, South Africa) and Gesine Mayer-Rath (Health Economics and Epidemiology Research Office and the University of Boston, USA) about cost-effectiveness of long-acting cabotegravir for PrEP in South Africa.

Read the full article:
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv